Evidence map›Paper›PMID 38263227›Full record

ReviewJournal of neuroinflammation2024

Modeling the neuroimmune system in Alzheimer's and Parkinson's diseases.

Wendy Balestri, Ruchi Sharma, Victor A da Silva, Bianca C Bobotis, Annabel J Curle, Vandana Kothakota, Farnoosh Kalantarnia, Maria V Hangad, Mina Hoorfar, Joanne L Jones and 4 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of neuroinflammation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Enteric Nervous System Damage by Food Contaminants: A Pathway to Neurodegeneration?Comprehensive reviews in food science and food safety · 2026
    Pooled it
  2. Pooled it
  3. Review
  4. Trehalose's untapped mechanisms in alzheimer's: gut-brain-autophagy signalling beyond the usual targets.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Computational Analysis andCurrent medicinal chemistry · 2026
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Wendy BalestriDepartment of Engineering, School of Science and Technology, Nottingham Trent University, Nottingham, UK.
Ruchi SharmaDepartment of Mechanical Engineering, University of Victoria, Victoria, Canada.
Victor A da SilvaDepartment of Mechanical Engineering, University of Victoria, Victoria, Canada.
Bianca C BobotisDivision of Medical Sciences, University of Victoria, Victoria, BC, Canada.
Annabel J CurleDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Vandana KothakotaDepartment of Biosciences, School of Science and Technology, Nottingham Trent University, Nottingham, UK.
Farnoosh KalantarniaDepartment of Mechanical Engineering, University of Victoria, Victoria, Canada.
Maria V HangadDivision of Medical Sciences, University of Victoria, Victoria, BC, Canada.
Mina HoorfarDepartment of Mechanical Engineering, University of Victoria, Victoria, Canada.
Joanne L JonesDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Marie-Ève TremblayDivision of Medical Sciences, University of Victoria, Victoria, BC, Canada.
Jehan J El-JawhariDepartment of Biosciences, School of Science and Technology, Nottingham Trent University, Nottingham, UK.
Stephanie M WillerthDepartment of Mechanical Engineering, University of Victoria, Victoria, Canada. willerth@uvic.ca.
Yvonne ReinwaldDepartment of Engineering, School of Science and Technology, Nottingham Trent University, Nottingham, UK. yvonne.reinwald@ntu.ac.uk.
University of Victoria · CANottingham Trent University · GBUniversity of Cambridge · GBUniversity of British Columbia · CA

Funding

Medical Research Council MR/S020934/1Medical Research Council MR/X503125/1
6 · The paper itself

Abstract

Parkinson's disease (PD) and Alzheimer's disease (AD) are neurodegenerative disorders caused by the interaction of genetic, environmental, and familial factors. These diseases have distinct pathologies and symptoms that are linked to specific cell populations in the brain. Notably, the immune system has been implicated in both diseases, with a particular focus on the dysfunction of microglia, the brain's resident immune cells, contributing to neuronal loss and exacerbating symptoms. Researchers use models of the neuroimmune system to gain a deeper understanding of the physiological and biological aspects of these neurodegenerative diseases and how they progress. Several in vitro and in vivo models, including 2D cultures and animal models, have been utilized. Recently, advancements have been made in optimizing these existing models and developing 3D models and organ-on-a-chip systems, holding tremendous promise in accurately mimicking the intricate intracellular environment. As a result, these models represent a crucial breakthrough in the transformation of current treatments for PD and AD by offering potential for conducting long-term disease-based modeling for therapeutic testing, reducing reliance on animal models, and significantly improving cell viability compared to conventional 2D models. The application of 3D and organ-on-a-chip models in neurodegenerative disease research marks a prosperous step forward, providing a more realistic representation of the complex interactions within the neuroimmune system. Ultimately, these refined models of the neuroimmune system aim to aid in the quest to combat and mitigate the impact of debilitating neuroimmune diseases on patients and their families.

Indexed as

Alzheimer DiseaseNeurodegenerative DiseasesParkinson DiseaseAnimalsHumansImmune SystemMicrogliaAlzheimer’s diseaseInflammationModelingNeurodegenerative diseasesNeuroimmune systemParkinson’s disease

Identifiers

PMID38263227
PMCPMC10807115
OpenAlexW4391133151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.